Skip to main content

Find Clinical Trials

Home
Conditions
Blood Protein Disorders

Clinical trial condition

Blood Protein Disorders

Explore clinical trials studying Blood Protein Disorders. Study availability and eligibility vary by location and protocol.

3,041 public trials 566 recruiting studies

Refine in advanced search Browse all conditions

Blood Protein Disorders trial results

Completed

Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy

NCT00002850

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +14 more
Locations: MBCCOP - Gulf Coast Mobile, Alabama, United States

Mobile Infirmary Medical Center Mobile, Alabama, United States

Cedar Rapids Oncology Associates Cedar Rapids, Iowa, United States

McCreery Cancer Center at Ottumwa Regional Ottumwa, Iowa, United States

View all 45 locations

View Trial Details

Completed

Volume Replacement With Albumin in Severe Sepsis

NCT00707122

Conditions: Blood Protein Disorders, Critical Illness, Disease Attributes, +14 more
Locations: Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico; Via F. Sforza 35 Milan, Italy

View Trial Details

Completed

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187

Conditions: Adenocarcinoma, Adnexal Diseases, Blast Crisis, +151 more
Locations: Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School New Brunswick, New Jersey, United States

View Trial Details

Completed

Canakinumab in Patients With Active Hyper-IgD Syndrome

NCT01303380

Conditions: Blood Protein Disorders, Brain Diseases, Brain Diseases, Metabolic, +16 more
Locations: Novartis Investigative Site Esplugues de Llobregat, Barcelona, Spain

Novartis Investigative Site Madrid, Spain

Novartis Investigative Site Valencia, Spain

View Trial Details

Completed

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

NCT00103506

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Alabaster, Alabama, United States

Surprise, Arizona, United States

Berkeley, California, United States

Loma Linda, California, United States

View all 108 locations

View Trial Details

Completed

UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma

NCT01621672

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: University of Arkansas for Medical Science-MIRT Little Rock, Arkansas, United States

View Trial Details

Completed

Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma

NCT00276536

Conditions: Blood Protein Disorders, Breast Cancer, Breast Diseases, +40 more
Locations: Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States

View Trial Details

Completed

Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00098566

Conditions: Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +38 more
Locations: Fred Hutchinson Cancer Research Center Seattle, Washington, United States

View Trial Details

Completed

A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT01485835

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: Colorado Blood Cancer Institute Denver, Colorado, United States

Emory University Hospital Midtown Atlanta, Georgia, United States

Emory University Winship Cancer Institute Atlanta, Georgia, United States

Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States

View Trial Details

Completed

Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)

NCT01971658

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: CHU Angers Angers, France

Hôpital Pitié-Salpétrière Paris, France

Centre Hospitalier de la région d'Annecy Annecy, Pringy, France

CHRU Hôpital Sud Amiens, France

View all 63 locations

View Trial Details